Trending...
- Living Abroad and IMPACT Group Awarded EMMA by Forum for Expatriate Management (FEM)
- Noted storyteller and technologist Angelica McKinley joins the board of NMHA
- $230 Million Class Action Settlement Reached From 2015 Santa Barbara Oil Spill
What I Wish I Knew a Year Ago About the Aesthetic Market and Where I'm Investing Now
VANCOUVER, British Columbia - eMusicWire -- In 1978, scientists isolated human insulin produced by genetically modified E. coli, marking the first biopharmaceutical derived from recombinant DNA technology. This radically new methodology for isolating enzymes and active ingredients shook biotechnology to the core, triggering a tsunami of discoveries. Since then, more than 250 therapeutic proteins and monoclonal antibodies have stolen the stage as standard of care.
In the last several years, this momentum carried over to cosmetics, as biotechnology and aesthetic medicines joined forces to isolate anti-aging skin products such as hyaluronic acid, kojic acid, and resveratrol, to name a few. But what new developments stand on the horizon? And to which direction should investors hone their gaze? Two emerging therapies, stem cell exosomes and gene therapy, scintillate brightly on the financial horizon as golden investment opportunities.
The global biotech aesthetic market size valued at USD 63.5 billion in 2021, with the compound annual growth rate (CAGR) projected to increase by 9.6% from 2022 to 2023, according to the aesthetic medicine market size report. Social distancing, sudden cuts in consumers' income levels, and temporary closures of beauty centers balanced the inevitable bottleneck in manufacturing and supply chains. The pandemic, however, saw the workforce shift to remote Zoom calls, forcing many to pay close attention to facial appearance. The market consequently saw a spike in non-invasive aesthetic treatments, with this segment dominating the market in 2021 with shares over 50%. The non-invasive aesthetic treatment market size was valued at USD 52 billion last year with a CAGR of 12.4%.
More on eMusic Wire
Currently, 45 market competitors compose the exosome industry, with 19 of them being established companies that have recently joined the race to develop aging-defying exosome technology. Some of these companies include: Galderma S.A., Johnson & Johnson, Allergen, El. En. SpA, Alma Lasers, Cynosure, Lumenis, Solta Medical, Syneron Candela, and Merz Pharma.
Up and coming regenerative biotech company Elevai shows award winning promise with stem cell exosome topical applications as the next generation of targeted anti-aging skin care. Elevai recently won the LaunchPad SBDC People's Choice Award at the 2022 Octane Aesthetics Tech Summit ("ATS") held in Newport Beach, California, for their proprietary stem cell exosome technology and products. The Elevai platform technology illuminates potential applications in regenerative medicine and in office medical skincare treatments.
Another company worth mentioning includes Jeune, a gene-based aesthetic subsidiary of Krystal biotech, that is currently operating the first-in-human Phase 1 clinical trial of an injectable gene therapy to stimulate production of collagen type III and reduce wrinkles. The injections were well tolerated and biopsies at the injection sites showed new collagen generation, an excellent first step to directly address biological changes in the skin associated with intrinsic and extrinsic aging.
More on eMusic Wire
Stem cell exosomes and gene therapy technologies will no doubt become the in office standard of care for regenerative and anti-aging technology, stealing the stage much in the same way that insulin radically changed diabetic care.
In the last several years, this momentum carried over to cosmetics, as biotechnology and aesthetic medicines joined forces to isolate anti-aging skin products such as hyaluronic acid, kojic acid, and resveratrol, to name a few. But what new developments stand on the horizon? And to which direction should investors hone their gaze? Two emerging therapies, stem cell exosomes and gene therapy, scintillate brightly on the financial horizon as golden investment opportunities.
The global biotech aesthetic market size valued at USD 63.5 billion in 2021, with the compound annual growth rate (CAGR) projected to increase by 9.6% from 2022 to 2023, according to the aesthetic medicine market size report. Social distancing, sudden cuts in consumers' income levels, and temporary closures of beauty centers balanced the inevitable bottleneck in manufacturing and supply chains. The pandemic, however, saw the workforce shift to remote Zoom calls, forcing many to pay close attention to facial appearance. The market consequently saw a spike in non-invasive aesthetic treatments, with this segment dominating the market in 2021 with shares over 50%. The non-invasive aesthetic treatment market size was valued at USD 52 billion last year with a CAGR of 12.4%.
More on eMusic Wire
- Noted storyteller and technologist Angelica McKinley joins the board of NMHA
- West Shore Construction Named #1 Hurricane Fabric Dealer in the Country
- Exterro Enhances Digital Forensic and Incident Response Automation with Major Upgrades to FTK® Connect
- Dungeon Forward Inks Multi Collection Deal with Nickelodeon and Paramount Consumer Products
- Music Icon Suga-T Stevens Plans Ceremony to Announce the Official Opening of a Museum Dedicated to the Contributions of Women and Girls and Wellness
Currently, 45 market competitors compose the exosome industry, with 19 of them being established companies that have recently joined the race to develop aging-defying exosome technology. Some of these companies include: Galderma S.A., Johnson & Johnson, Allergen, El. En. SpA, Alma Lasers, Cynosure, Lumenis, Solta Medical, Syneron Candela, and Merz Pharma.
Up and coming regenerative biotech company Elevai shows award winning promise with stem cell exosome topical applications as the next generation of targeted anti-aging skin care. Elevai recently won the LaunchPad SBDC People's Choice Award at the 2022 Octane Aesthetics Tech Summit ("ATS") held in Newport Beach, California, for their proprietary stem cell exosome technology and products. The Elevai platform technology illuminates potential applications in regenerative medicine and in office medical skincare treatments.
Another company worth mentioning includes Jeune, a gene-based aesthetic subsidiary of Krystal biotech, that is currently operating the first-in-human Phase 1 clinical trial of an injectable gene therapy to stimulate production of collagen type III and reduce wrinkles. The injections were well tolerated and biopsies at the injection sites showed new collagen generation, an excellent first step to directly address biological changes in the skin associated with intrinsic and extrinsic aging.
More on eMusic Wire
- M.King Media's 2nd Special Report "Black America: We Have A Problem" Is Now Streaming
- Blockchain Startup Aimed at Financial Inclusion Secures 25 Million Dollar Capital Commitment
- HR Tech Awards Recognizes Valuable Contributors to Hiring, Retention, and More
- The Martini Shot Launches A Sci-Fi Martial Arts and Fashion Franchise
- 1040 Abroad: Live tax-free if you earn less than $112,000
Stem cell exosomes and gene therapy technologies will no doubt become the in office standard of care for regenerative and anti-aging technology, stealing the stage much in the same way that insulin radically changed diabetic care.
Source: Braeden William Lichti
0 Comments
Latest on eMusic Wire
- 227's™ YouTube Chili' BUFFALO CHIP Spicy' Concert! SNOOP DOGG x BUCKCHERRY! #NIKE'Spicy' NBA!
- Gospel Recording Artist Win Thompkins Launches a New Soul Music Project
- Growing Up Beckham: Kordell Beckham Makes Runway Debut
- Comedian Don Barnhart Brings Nightly Laughter To Jokesters Comedy Club In Las Vegas
- Ntozake Shange's For Colored Girls Revival Nominated for 7 Tony Awards
- Premium Brands Enter Santé Wine & Spirits Competition
- Green Science Solutions To Demo Gold Standard Cleaning Platform For Healthier Senior Living At Argentum 2022
- Kano Laboratories Introduces Kroil Penetrant with Graphite for High Temperature Environments
- Teenear Samples Brandy's "The Boy Is Mine" on her Single Release Ain't Mine - Available May 13th on all streaming platforms
- African Arts Academy Hosts Modern Ethnic Fashion Show in San Francisco communities
- La fundacion Dranoff Presenta Celebración de Jazz Clásico y Grandes Afrocubanos
- 1040 Abroad offers an incentive to existing customers to refer a friend, while reminding expatriates of the upcoming June 15, 2022 deadline
- IndyGeneUS AI Awarded Grant Funding through QuickFire Challenge
- Five to Flow and NTeli Form Strategic Partnership to Improve Business Performance on Technology Transformation Programs
- Asia's First Decentralized NFT-Fi Platform SOLARR Raises $2M to Bring NFT Use Cases Mainstream
- The Business of Reversing Broken Homes
- NEAT Glass to be the Official Judging Glass of The CHILLED 100 Spirits Awards
- BACA Systems Hires Account Executives to Lead Business Development, Manage Customer Relationships in Six States
- Natron STC 370HP Low coefficient of silicone coating gets USP Cytotoxicity certification
- Braconomics Harlette Capital Ltd Contribution to Saudi Arabia Economy $33Bill each year for 11 years